Randox Laboratories has come up with a biochip array for simultaneous quantitative diagnosis of three tumor markers in a single patient sample. This provides a quick, reliable and low-cost method for the screening of prostate cancer. The currently used PSA measurement is not a sufficient diagnostic tool in itself. The new technology from Randox is based on an ELISA format.